Artificial intelligence (AI) isn't the only industry with explosive growth potential.

The business may not be as strong as its performance this year suggests.

2025 was a catalyst year for biotech and drug stocks. While the year began on a cautious note for the sector due to concerns over potential tariffs on pharmaceutical imports, the sector rebounded in ...

This biotech has candidates in late-stage clinical development.

On January 26, UBS lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $380 and kept a Buy rating on the stock.

Amid the expected positive clinical trial results, Legend Biotech has also reiterated plans to achieve profitability in 2026.

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among ...

Plenty of analysts on Wall Street think so. The company boasts an average price target of $93.39 (according to Yahoo! Finance ...

Both companies may succeed in this industry.

Emkay Global Financial is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 637 in ...

After three consecutive years of above-average gains, the S&P 500 is off to a volatile start to 2026. The S&P 500's forward earnings multiple of 22.2 is currently well above its 10-year average of 18.

Overview:  Stocks under $10, such as Sidus Space and Masonglory, show strong 3-month growth with a high future chance.Mining ...